Human Factor Ix
Mostrando 1-12 de 119 artigos, teses e dissertações.
-
1. Causes of death and mortality trends related to hemophilia in Brazil, 1999 to 2016
ABSTRACT Introduction Multiple cause of death methodology enhances mortality studies beyond the traditional underlying cause of death approach. Aim: This study aims to describe causes of death and mortality issues related to haemophilia with the use of multiple-cause-of-death methodology. Methods: Annual male haemophilia mortality data was extracted from
Hematol., Transfus. Cell Ther.. Publicado em: 2021-06
-
2. Isolated biomolecules of pharmacological interest in hemostasis from Cerastes cerastes venom
Biomolecules from Cerastes cerastes venom have been purified and characterized. Two phospholipases isolated from Cerastes cerastes venom share 51% of homology. CC2-PLA2 exhibits antiplatelet activity that blocks coagulation. CCSV-MPase, a non-hemorrhagic Zn2+-metalloproteinase, significantly reduced the plasmatic fibrinogen level and hydrolyzes only its Bβ
J. Venom. Anim. Toxins incl. Trop. Dis. Publicado em: 01/05/2013
-
3. Animais transgênicos utilizados como biorreatores
The increasing demand for production of pharmaceutical interest recombinant proteins has been the goal for the development of additional systems to its production on a large scale and reduced costs. Eukaryotes expression systems are possible alternatives to the production of recombinant protein (Leite, 2000). The secretion of these polypeptides in the milk o
Publicado em: 2008
-
4. ExpressÃo de cinco diferentes proteÃnas de interesse farmacolÃgico em sementes transgÃnicas de soja [Glycine Max L. (Merril)]
Superior plants represent a convenient system for large-scale production of heterologous proteins. Its potential has been confirmed by the commercial success of such production systems, based on genetic transformation of a broad range of vegetable species, resulting in efficient production of more than 100 different heterologous proteins. A representative pe
Publicado em: 2008
-
5. Production of specific polyclonal antibodies anti-human factor IX
Neste trabalho foram produzidos anticorpos policlonais anti-fator IX humano em coelhos New Zealand imunizados com FIX humano (hFIX) comercial puro (Octanyne®, Octapharma, EUA). O soro contendo as imunoglobulinas anti-hFIX foi útil para a detecção do antígeno hFIX em frações do plasma humano submetido a cromatografia de troca iônica. Imunoensaios (ELI
Brazilian Archives of Biology and Technology. Publicado em: 2006-07
-
6. Structure-activity relationship of synthetic peptides derived from human acidic Fibroblast Growth Factor Site 2 primary sequence / Peptídeos de conformação restrita relacionados ao sítio 2 do fator de crescimento de fibroblastos ácido humano (hFGF-1): estudo sobre estrutura e atividade
Na busca por agonistas, antagonistas e inibidores de natureza peptídica do fator de crescimento de fibroblastos ácido humano (hFGF-1), iniciamos o presente trabalho fazendo uma análise conformacional teórica do peptídeo Ac- WFVGLKKNGSSKRGPRT-NH2 (107-123 [hFGF-1]). Em trabalho anterior, este composto havia se mostrado um agonista da atividade mitogênic
Publicado em: 2000
-
7. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
Two structurally different forms of activated human Factor IX (Factor IXa alpha and IXa beta) have been previously reported to have essentially identical clotting activity in vitro. Although it has been shown that activated Factor IX Chapel Hill, an abnormal Factor IX isolated from the plasma of a patient with mild hemophilia B, and normal Factor IXa alpha a
-
8. An alternative approach to somatic cell gene therapy.
Mouse primary skin fibroblasts were infected with a recombinant retrovirus containing human factor IX cDNA. Bulk infected cells capable of synthesizing and secreting biologically active human factor IX protein were embedded in collagen, and the implant was grafted under the epidermis. Sera from the transplanted mice contain human factor IX protein for at lea
-
9. Kinetics of the Factor XIa catalyzed activation of human blood coagulation Factor IX.
The kinetics of activation of human Factor IX by human Factor XIa was studied by measuring the release of a trichloroacetic acid-soluble tritium-labeled activation peptide from Factor IX by a modification of a method described for bovine Factor IX activation by Zur and Nemerson (Zur, M., and Y. Nemerson, 1980, J. Biol. Chem., 255:5703-5707). Initial rates of
-
10. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
Hemophilia B Chapel Hill is a mild hereditary hemorrhagic disorder in which the factor IX antigen is present in normal amounts but factor IX biological activity is markedly reduced. Previous studies have demonstrated that purified factor IX Chapel Hill has 8% of the activity of normal human factor IX and that the activation of factor IX Chapel Hill is defect
-
11. Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B.
In aiming to develop a gene therapy approach for hemophilia B, we expressed and characterized human factor IX in rat capillary endothelial cells (CECs). Moloney murine leukemia virus-derived retrovirus vectors that contain human factor IX cDNA linked to heterologous promoters and the neomycin-resistant gene were constructed and employed to prepare recombinan
-
12. Expression of human factor IX in mice after injection of genetically modified myoblasts.
Hemophilia B is an X chromosome-linked recessive bleeding disorder. To develop a somatic gene therapy for this disease, we have examined whether mouse skeletal myoblasts can serve as efficient vehicles for systemic delivery of recombinant factor IX. When mouse myoblasts (C2C12) transduced with a Moloney murine leukemia virus-based vector containing the bacte